Halozyme Therapeutics | HALO - Operating Profit



Halozyme Therapeutics reported $202.44M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amarin USD -16755000 35.77M Mar/2025
Amgen USD 2.66B 1.37B Jun/2025
Baxter International USD 272M 214M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
DBV Technologies USD -41110000 14.49M Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Halozyme Therapeutics USD 202.44M 60.91M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
MannKind USD -43411000 65.7M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
United Therapeutics USD 276.9M 105.9M Jun/2025